STF Management LP Cuts Stock Holdings in Astrazeneca Plc $AZN

STF Management LP reduced its position in shares of Astrazeneca Plc (NYSE:AZN) by 61.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,394 shares of the company’s stock after selling 5,349 shares during the period. STF Management LP’s holdings in Astrazeneca were worth $596,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AZN. Bank of Montreal Can raised its position in Astrazeneca by 344.6% in the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after acquiring an additional 2,695,793 shares in the last quarter. Holocene Advisors LP raised its position in Astrazeneca by 41.8% in the third quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after acquiring an additional 1,807,565 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its position in Astrazeneca by 11,190.9% in the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,806,877 shares of the company’s stock worth $317,107,000 after acquiring an additional 1,790,874 shares in the last quarter. Raymond James Financial Inc. raised its position in Astrazeneca by 64.8% in the second quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after acquiring an additional 1,487,662 shares in the last quarter. Finally, Bank of America Corp DE raised its position in Astrazeneca by 4.7% in the third quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Trading Down 1.8%

Shares of AZN stock opened at $181.62 on Friday. Astrazeneca Plc has a fifty-two week low of $136.16 and a fifty-two week high of $212.71. The stock has a market cap of $281.67 billion, a P/E ratio of 27.27, a P/E/G ratio of 1.49 and a beta of 0.26. The business has a fifty day simple moving average of $192.38 and a 200-day simple moving average of $182.04. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The business had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. On average, analysts forecast that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

AZN has been the subject of several research analyst reports. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Thursday. Citigroup initiated coverage on shares of Astrazeneca in a report on Tuesday, January 27th. They issued a “buy” rating for the company. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and an average price target of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.